1h Free Analyst Time
The parkinsons disease (PD) drugs market is forecasted to grow by USD 1.77 billion during 2024-2029, accelerating at a CAGR of 5.7% during the forecast period. The report on the parkinsons disease (PD) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of pd, growing healthcare expenditure, and increasing awareness and education.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The parkinsons disease (PD) drugs market is segmented as below:
By Drug Class
- Carbidopa-levodopa
- Anticholinergics
- Dopamine agonists
- MAO-B inhibitors
- Others
By Distribution Channel
- Retail pharmacy
- Hospital pharmacy
- Online pharmacy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the parkinsons disease (PD) drugs market covers the following areas:
- Parkinsons Disease (PD) Drugs Market sizing
- Parkinsons Disease (PD) Drugs Market forecast
- Parkinsons Disease (PD) Drugs Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Drug Class
9 Market Segmentation by Distribution Channel
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global parkinsons disease (PD) drugs market: AbbVie Inc., ABL Bio Inc., Acadia Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Ipsen Pharma, Kyowa Kirin Co. Ltd., Novartis AG, Orion Corp, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, and ZAMBON CO S.P.A..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is new drug approvals."
According to the report, one of the major drivers for this market is the rising prevalence of pd.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- ABL Bio Inc.
- Acadia Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc.
- Boehringer Ingelheim International GmbH
- Eisai Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- H Lundbeck AS
- Ipsen Pharma
- Kyowa Kirin Co. Ltd.
- Novartis AG
- Orion Corp
- Sunovion Pharmaceuticals Inc.
- Supernus Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB SA
- ZAMBON CO S.P.A.
